Improved survival of chimeric antigen receptor‐engineered T (CAR‐T) and tumor‐specific T cells caused by anti‐programmed cell death protein 1 single‐chain variable fragment‐producing CAR‐T cells

Chimeric antigen receptor‐engineered T (CAR‐T)‐cell therapy holds significant promise for the treatment of hematological malignancies, especially for B‐cell leukemia and lymphoma. However, its efficacy against non‐hematological malignancies has been limited as a result of several biological problems...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Masao, Sakoda, Yukimi, Adachi, Keishi, Nagano, Hiroaki, Tamada, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778656/
https://www.ncbi.nlm.nih.gov/pubmed/31432594
http://dx.doi.org/10.1111/cas.14169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778656/
https://www.ncbi.nlm.nih.gov/pubmed/31432594
http://dx.doi.org/10.1111/cas.14169

Ejemplares similares